Brief: R1 Therapeutics Announces Launch With An Oversubscribed $77.5 Million Series A Financing

Davita

17/03/2026 11:00

March 17 (Reuters) - DaVita Inc DVA.N:

R1 THERAPEUTICS: EXCLUSIVE GLOBAL LICENSE TO DEVELOP, COMMERCIALIZE AP306 OUTSIDE OF GREATER CHINA FROM ALEBUND PHARMACEUTICALS

R1 THERAPEUTICS ANNOUNCES LAUNCH WITH AN OVERSUBSCRIBED $77.5 MILLION SERIES A FINANCING

R1 THERAPEUTICS: PROCEEDS FROM SERIES A FINANCING TO FUND R1'S GLOBAL DEVELOPMENT PROGRAM OF AP306

R1 THERAPEUTICS: FINANCING WAS CO-LED BY ABINGWORTH, F-PRIME, & DAVITA VENTURE GROUP, WITH PARTICIPATION FROM CURIE.BIO, SYMBIOSIS, & U.S. RENAL CARE

Source text: [ID:]

Further company coverage: DVA.N

 ((Reuters.Briefs@thomsonreuters.com;))